SLC5A2 and type 2 diabetes mellitus: In those patients with type 2 diabetes and established ASCVD, or in those with established chronic kidney disease or heart failure, the consensus recommends use of GLP‐1RAs or SGLT2 inhibitors with proven CV benefits.35